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function due to long-term consequences
of fragmented dermal collagen micro-
environment in photodamaged human
skin.
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TO THE EDITOR
Mutations of the IL36RN gene have
been recently identified in patients
affected by generalized pustular psoria-
sis (GPP), a neutrophilic dermatosis that
presents as an acute pustular eruption
accompanied by features of systemic
inflammation (Marrakchi et al., 2011;
Onoufriadis et al., 2011). Although GPP
is traditionally classified as a variant of
psoriasis vulgaris (PV; Griffiths and
Barker, 2010), our group has
demonstrated that the two conditions
are genetically distinct (Onoufriadis
et al., 2011).
In this context, the aim of this study
was to characterize the spectrum of
psoriasis-associated pustular phenotypes
that are caused by IL36RN alleles. To
achieve this objective, we analyzed an
extended collection of GPP cases and,
in parallel, investigated the possibility
that IL36RN may contribute to palmar-
plantar pustulosis (PPP) and acroderma-
titis continua of hallopeau (ACH), two
acral forms of pustular psoriasis that
have been historically grouped with
GPP (Griffiths and Barker, 2010), and
which are also thought to be genetically
distinct from PV (Asumalahti et al.,
2003).
We sequenced the four IL36RN cod-
ing exons in 84 GPP, 9 ACH, and 139
PPP cases (Supplementary Table S1
online). Owing to the rarity of the
examined diseases, we defined as
potentially pathogenic any non-synon-
ymous substitution, frameshift mutation,
or splicing defect that had a minor allele
frequency (MAF)o0.01 in the relevant
ethnic group. We observed homozy-
gous/compound heterozygous alleles
meeting the above criteria in 7/84 GPP
patients, thus validating previous obser-
vations of genetic heterogeneity in this
disease (Onoufriadis et al., 2011; Li
et al., 2012; Sugiura et al., 2012).
Importantly, we also identified
recessive IL36RN variants in 2/9 ACH
and 3/139 PPP patients (Table 1).
The most prevalent allele in the
European population was the previously
characterized p.Ser113Leu substitution
(Onoufriadis et al., 2011), which was
found in all three patient groups. The
most frequent change in the Asian data
set was the c.115þ6T4C variant,
which is known to disrupt the splicing
of exon 3, leading to the synthesis of a
truncated protein (Farooq et al., 2012).
As our resource did not include Asian
PPP or ACH patients, we could not
establish whether the c.115þ6T4C
allele also contributes to these conditions.
An analysis of intragenic SNP haplo-
types indicated that both p.Ser113Leu
and c.115þ 6T4C are likely to have
Abbreviations: ACH, acrodermatitis continua of hallopeau; FMF, familial Mediterranean fever; GPP,
generalized pustular psoriasis; MAF, minor allele frequency; PPP, palmarplantar pustulosis; PV, psoriasis
vulgaris
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spread as the result of founder effects
(Supplementary Table S2 online).
The other IL36RN variants observed
in homozygous/compound heterozy-
gous patients were two missense sub-
stitutions (p.Lys35Arg, p.Arg102Trp;
Table 1) that were classified as dama-
ging by the SIFT (Kumar et al., 2009)
and/or PolyPhen (Adzhubei et al., 2010)
pathogenicity prediction tools. It is
noteworthy that homology modeling of
IL36-Ra (the protein encoded by
IL36RN) indicated that Lys35 maps in
proximity to the residues that mediate
binding to the protein receptor
(Figure 1).
It is interesting to note that we uncov-
ered heterozygous changes in 4 PPP
and 6 GPP cases, who carried the
previously mentioned c.115þ6T4C
and p.Ser113Leu alleles. As all reported
IL36RN mutations have been found in a
recessive state (Marrakchi et al., 2011;
Onoufriadis et al., 2011; Sugiura et al.,
2012), we searched for a second disease
allele in these patients. We performed a
long-range PCR of the genomic region
that encompasses IL36RN coding exons
and intervening introns. We consistently
observed a single amplification product,
excluding the possibility that these
individuals may carry intragenic
deletions or duplications (Supple-
mentary Figure S1 online). We also
sequenced a 1007-bp putative promoter
fragment (Supplementary Table S3
online), but did not uncover any variants
with an MAFo0.01.
To assess the likelihood of repeatedly
observing a rare IL36RN allele by
chance, we examined the prevalence
of the p.Ser113Leu substitution in the
Caucasian data set analyzed by the
NHLBI GO Exome Sequencing Project.
We found that the frequency of this
variant among the European patients
who did not carry recessive IL36RN
changes significantly exceeded that
observed in 8,600 control chromosomes
(1.7 vs. 0.3%; P¼0.004). This suggests
that the p.Ser113Leu allele may have
pathogenic potential even in the hetero-
zygous state.
We carefully reviewed the clinical
records of the 22 individuals carrying
IL36RN variants. We observed no sig-
nificant dissimilarities in age at onset,
prevalence of PV, or clinical presenta-
tion between the cases bearing two
IL36RN alleles and the rest of the study
cohort. Similarly, the severity of the
disease did not differ significantly in
patients bearing single heterozygous
Table 1. Summary of patients bearing IL36RN alleles with pathogenic potential
Patient ID Sex Ethnicity IL36RN variants Disease
Age of onset (years;
disease duration) PV
ACH-I F European (British) p.Arg102Trp/p.Ser113Leu ACH 37 (1) Y
ACH-II F European (Swiss) p.Ser113Leu/p.Ser113Leu ACH 67 (10) Y
GLA-I M European (British) p.Lys35Arg/p.Ser113Leu GPP 29 (13) N
GLA-II M European (British) p.Ser113Leu/p.Ser113Leu GPP 26 (10) N
GLA-III M European (British) p.Ser113Leu1 GPP 39 (12) N
MAL-I F Asian (Malay) c.115þ6 T4C/ c.115þ6 T4C GPP 37 (8) Y
MAL-II F Asian (Chinese) c.115þ6T4C/ c.115þ6T4C GPP 21 (9) Y
MAL-III F Asian (Malay) c.115þ6T4C1 GPP 9 (31) N
MAL-IV M Asian (Malay) c.115þ6T4C1 GPP 42 (10) Y
MAL-V F Asian (Malay) c.115þ6T4C1 GPP 12 (21) Y
MAL-VI M Asian (Chinese) c.115þ6T4C/ c.115þ6T4C GPP 12 (32) N
MAL-VII M Asian (Malay) c.115þ6T4C/p.Ser113Leu GPP 8 (3) Y
MAL-VIII F Asian (Malay) c.115þ6 T4C/ c.115þ6T4C GPP 2 (39) Y
MAL-IX F Asian (Chinese) c.115þ6T4C1 GPP 40 (22) Y
MAL-X M Asian (Chinese) c.115þ6T4C1 GPP 12 (19) Y
STJ-I M European (British) p.Ser113Leu/p.Ser113Leu PPP 5 (41) Y
STJ-II F European (British) p.Ser113Leu/p.Ser113Leu PPP 17 (47) Y
STJ-III M European (British) p.Ser113Leu/p.Ser113Leu PPP 24 (14) N
P-GLA-I F European (British) p.Ser113Leu1 PPP 77 (13) N
P-GLA-II F European (British) p.Ser113Leu1 PPP NA Y
P-MAN-I M European (British) p.Ser113Leu1 PPP NA NA
P-MAN-II F European (British) p.Ser113Leu1 PPP NA NA
Abbreviations: ACH, acrodermatitis continua of hallopeau; F, female; GPP, generalized pustular psoriasis; M, male; N, no; NA, the information was not
available; PPP, palmarplantar pustulosis; PV, psoriasis vulgaris; Y, yes.
All cases were sporadic and unrelated.
1Variant observed in heterozygosity, in the absence of a second pathogenic allele (individuals MAL-III, MAL-IV, and MAL-X also carried a p.Pro76Leu change,
but sequencing of cloned PCR products demonstrated that this substitution is always found on the same chromosome as the c.115þ 6T4C allele).
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changes, compared with those harbor-
ing homozygous/compound heterozy-
gous alleles.
Our data indicate that IL36RN
alleles are associated with a phenotypic
spectrum that encompasses ACH and
PPP, as well as GPP. Importantly, we
observed both homozygous, compound
heterozygous, and single heterozygous
IL36RN substitutions. Although it is the-
oretically possible that the heterozygous
individuals may harbor a second disease
allele (e.g., a large genomic duplication
which could not have been detected by
our long-PCR assay), the most likely
interpretation of our findings is that
some GPP/PPP patients present with a
single IL36RN mutation. This is reminis-
cent of the genetic makeup of familial
Mediterranean fever (FMF), an autoin-
flammatory condition that is associated
with homozygous and heterozygous
mutations of the MEFV gene (Kastner
et al., 2010). The possibility that
modifying alleles at other loci may
contribute to FMF has been invoked to
explain disease occurrence in individuals
bearing single MEFV mutations (Kastner
et al., 2010). Thus, it is possible that the
GPP and PPP cases harboring a single
IL36RN substitution may represent cases
of tri-allelic disease inheritance. The
screening of further clinical resources
should identify sufficient numbers of
heterozygous patients to allow an
assessment of this hypothesis by means
of exome sequencing.
We only observed IL36RN mutations
in a minority of patients, indicating the
likely involvement of other gene loci
and suggesting that pustular forms of
psoriasis may be classified on the basis
of their genetic etiology in the future. In
this context, it is noteworthy that indi-
viduals with IL36RN mutations upregu-
late IL-1 production in response to IL-36
stimulation (Onoufriadis et al., 2011).
This suggests that the symptoms of
these particular patients might be
caused by excessive IL-1 production
and may therefore be treated by IL-1
blockade. Further investigations will
obviously be required to validate the
role of IL-1 as a driver of IL36RN-asso-
ciated pustular disease. Such experi-
ments hold the promise of translating
the results of genetic studies into
significant improvement in patient care.
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Figure 1. Characterization of the IL36RN variants uncovered in this study. Sequence chromatograms
for each substitution are shown on the left, whereas the right end panels show the position of the
relevant amino acids within the three-dimensional structure of the IL-36Ra protein. Key regions
(loop 3–4, residues 30–41 and loop 7–8, residues 82–98) and amino acids (His32, Lys38, Tyr89,
Glu94, Lys96) mediating the interaction of IL-36ra with its cognate receptor are highlighted. The
pSer113Leu variant is not shown, as this substitution has been previously characterized (Onoufriadis et al.,
2011).
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TO THE EDITOR
Generalized vitiligo is a disease in
which patches of depigmented skin
and overlying hair result from autoim-
mune destruction of melanocytes in
involved regions (Spritz, 2012). Clinic-
based studies cite high prevalence of
vitiligo in India, up to 8.8% (e.g., Handa
and Kaur, 1999), although population-
based surveys report much lower
prevalence, 0.46% in Calcutta (Das
et al., 1985) and 1.79% in South
Gujarat (Mehta et al., 1973).
Vitiligo is a distressing cosmetic pro-
blem in individuals of dark skin photo-
types, owing to striking contrast
between lesions and unaffected skin.
This may explain the reported high
prevalence of vitiligo in India and the
negative impact on perceived quality of
life in this population (Parsad et al.,
2003). Indeed, vitiligo has long been
recognized in India (Singh et al., 1974),
the specific use of UV light treatment
was pioneered in India (Menon, 1945),
and some of the earliest genetic studies
of vitiligo were carried out there: of
ABO blood groups, a1-antitrypsin, and
haptoglobin, and subsequent candidate
gene studies, including GCH1, ACE,
CAT, CTLA4, GPX1, IL4, MBL2, and
PTPN22, most yielding negative or
conflicting results. Recently, Singh
et al. (2012) tested the genetic asso-
ciation of vitiligo in Indian patients with
HLA-A, -B, -C in the major histocom-
patibility complex (MHC) class I region
and HLA-DRB1 in the class II region,
identifying primary genetic association
with HLA-DRB1*07:01.
Here, we describe a more compre-
hensive genetic association study of
generalized vitiligo on the Indian sub-
continent, using the Immunochip (Cortes
and Brown, 2011) to screen 196,524
single-nucleotide polymorphisms (SNPs)
in 128 loci previously implicated in
autoimmune and inflammatory diseases,
including 9,441 SNPs spanning the
extended MHC on chromosome 6p.
Our results suggest that there are at
least two independent association
signals in the MHC class II region, one
located upstream of HLA-DRA and the
other located between HLA-DRB1 and
HLA-DQA1, generally similar to what
we previously found in a genome-wide
association study of vitiligo in European-
derived whites (EUR) (Jin et al., 2010).
Our initial study group consisted of
255 patients with generalized vitiligo
and 377 unrelated non-vitiligo controls
of Indian subcontinent (Pakistan, India,
Sri Lanka, and Bangladesh) derivation.
After quality control procedures, data for
120,724 remaining SNPs from 251
remaining cases were compared with
those from 349 remaining controls. Sug-
gestive association signals were consid-
ered as clusters of nearby SNPs with
trend P-values o105. The Interna-
tional Immunochip Consortium has
agreed on a genome-wide significance
criterion of Po5 10 8 for studies
utilizing the Immunochip (Cortes and
Brown, 2011).
As shown in Figure 1a and Supple-
mentary Table S1 online, the only highly
suggestive association signals were in
the MHC class II gene region (Figure 1b),
from rs3134942 (chr6:32168770) to
rs2856674 (chr6:32659644), spanning
the upstream part of NOTCH4 through
HLA-DQB1. The principal region of
association encompassed c6orf10--
BTNL2–HLA-DRA–HLA-DRB5–HLA-
DRB1–HLA-DQA1 (Figure 1b), with
extensive linkage disequilibrium (LD)
through this region in this population
(Figure 1c). One SNP, rs482044, located
toward the centromeric end of the region,
between HLA-DRB1 and HLA-DQA1,
achieved genome-wide significance
(G allele; P¼1.94108, odds ratio
(OR)¼ 1.93; Table 1), remaining signifi-
cant (P¼4.86  108) even after
correction for the observed genomic
inflation factor l¼1.06.
To determine which SNPs in the
MHC class II region represent primary
association with vitiligo versus are sig-
nals secondary to LD, we applied a
backward regression procedure, com-
paring a model including the seven most
significant MHC class II SNPs to alter-
native models in which each SNP was
removed one by one. This analysis
suggested that this region contains two
independent associated loci, one repre-
sented by rs482044-G (located between
HLA-DRB1 and HLA-DQA1) and the
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